Drug Profile


Alternative Names: NW-3509; NW-3509A

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Newron Pharmaceuticals
  • Class Antidepressants; Antiepileptic drugs; Antimanics; Antipsychotics; Non-opioid analgesics
  • Mechanism of Action Dopamine D2 receptor antagonists; Nav1.3 voltage-gated sodium channel inhibitors; Nav1.7-voltage-gated-sodium-channel-inhibitors; Nav1.8 voltage-gated sodium channel inhibitors; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia

Most Recent Events

  • 03 Jan 2017 Interim adverse events and efficacy data from a phase IIa trial in Schizophrenia (Adjunctive treatment) released by Newron
  • 01 Jan 2017 Newron completes a phase II trial in Schizophrenia (Adjunctive treatment) in USA (PO) (NCT02624167)
  • 02 Dec 2015 Phase-II clinical trials in Schizophrenia (Adjunctive treatment) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top